Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK2 | Q13002 | 3/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193465 | 0.91 | ALDH1A1 (0.42) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL12334969 | 0.87 | GRIK2 (0.48) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL980280 | 0.87 | GRIK2 (0.48) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL980519 | 0.87 | PSEN1 (0.46) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL10095297 | 0.87 | GRIK2 (0.52) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL10095252 | 0.87 | GRIK2 (0.60) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL982491 | 0.86 | GRIK2 (0.49) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL979587 | 0.85 | GRIK2 (0.52) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL10095470 | 0.85 | GRIK2 (0.59) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 | |
| SCHEMBL10095253 | 0.84 | GRIK2 (0.62) | GRIK2GRIK1KDM4EMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| EP-1771169-A1 | METHODS FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060223863-A1 | Methods for treating Hepatitis C | KARP GARY M | 2006-10-05 | — | — | US | disclosed |
| US-20060189606-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2006-08-24 | — | — | US | disclosed |
| WO-2006019831-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | GRIK2 3701/4885GRIK1 3372/4885KDM4E 3422/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | GRIK2 4399/4885GRIK1 4352/4885KDM4E 3703/4885 |
| US-20060189606-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | GRIK2 2948/4885GRIK1 2562/4885KDM4E 4020/4885 |
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | GRIK2 2948/4885GRIK1 2562/4885KDM4E 4020/4885 |
| US-20060223863-A1 | Methods for treating Hepatitis C | OAT, HAVCR2, HCCS | GRIK2 4399/4885GRIK1 4352/4885KDM4E 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.